Ara-C, the standard medicine to treat acute myeloid leukemia, is an anti-cancer agent with a mechanism of action that blocks DNA synthesis and replication, however it has been reported to have no effects on solid tumors. Kainos Medicine tries to overcome the limitation of cytotoxic anti-cancer agents, such as Ara-C, by discovering the best-in-class nucleic acid derivative that are efficacious to hematological cancers and solid tumors and can be taken both orally and through intravenous injection.

Through our core competency of medicinal chemistry technology, we have discovered a candidate compound based on the inhibition of BRD4 (one type of bromodomain) and currently conducting strategic joint development program with the Chinese pharmaceutical company.